62,785 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Acquired by XTX Topco Ltd

XTX Topco Ltd purchased a new stake in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 62,785 shares of the company’s stock, valued at approximately $78,000. XTX Topco Ltd owned approximately 0.10% of SELLAS Life Sciences Group at the end of the most recent quarter.

Separately, Renaissance Technologies LLC purchased a new stake in shares of SELLAS Life Sciences Group during the second quarter valued at $39,000. 17.38% of the stock is owned by institutional investors.

SELLAS Life Sciences Group Price Performance

Shares of SLS stock opened at $0.89 on Friday. The business has a fifty day moving average of $1.15 and a 200 day moving average of $1.21. SELLAS Life Sciences Group, Inc. has a 1 year low of $0.50 and a 1 year high of $1.72. The firm has a market capitalization of $62.50 million, a price-to-earnings ratio of -1.29 and a beta of 2.39.

SELLAS Life Sciences Group Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.